Video

Dr. Andre Goy Explains Marginal Zone Lymphoma

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses marginal zone lymphoma.

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses marginal zone lymphoma.

Marginal zone lymphoma is uncommon, and makes up about 5% to 8% of all lymphomas. However, much can be learned from the rare disease, says Goy.

Studies have identified several types of marginal zone lymphoma that are antigenically driven. The most common and well-defined type is gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Antibiotics are often used as the primary treatment for MALT lymphoma of the stomach.

There is also skin MALT lymphoma, which has been linked in Europe to Lyme disease. This can also be treated with antibiotics, says Goy. Additionally, there is MALT lymphoma of the lungs.

MALT lymphoma can occur after chronic stimulation that generates enough mutation to drive the cell to become cancerous, says Goy. Overtime, a MALT lymphoma can become independent lymphoma not responsive to antibiotics, and could potentially transform.

Related Videos
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD